Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals has initiated a Phase 1a clinical trial with the first participant dosed with AUR200, aimed at treating autoimmune diseases by targeting two key proteins. The study will evaluate the safety and efficacy of AUR200, with results expected by the first half of 2025. Aurinia is optimistic about AUR200’s potential as a superior treatment option, given its high potency and specificity demonstrated in preclinical research.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
